PEPG
PepGen Inc.5.52
+0.05+0.91%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
379.49MP/E (TTM)
-Basic EPS (TTM)
-2.82Dividend Yield
0%Recent Filings
10-K
FY2025 results
PepGen posted FY2025 net losses of $89.7M, nearly flat y/y from $90.0M, with R&D expenses dipping 7% to $71.0M as DMD programs wound down post disappointing CONNECT1 results while DM1 efforts ramped, including FREEDOM Phase 1 topline (53.7% mean splicing correction at 15mg/kg Q3) and FREEDOM2 Phase 2 enrollment (5mg/kg cohort complete, data Q1 2026). Cash swelled to $148.5M after $108M 2025 offering, funding operations into H2 2027. Q4 saw FREEDOM2 10mg/kg dosing start amid FDA partial hold on preclinical tox data. Year-end shares outstanding: 69.1M. FDA partial hold risks DM1 momentum.
8-K
FDA partial hold on FREEDOM2
8-K
PGN-EDODM1 Phase 1 data shines
PepGen updated its corporate presentation on March 4, 2026, highlighting Phase 1 FREEDOM data for PGN-EDODM1 in DM1: dose-dependent splicing correction up to 53.7% at 15 mg/kg, with 87.5% of participants improved, and generally well-tolerated profile. Phase 2 FREEDOM2 multiple-ascending dose study is enrolling at 5-12.5 mg/kg despite U.S. FDA partial hold. Cash runway extends into 2H 2027. FREEDOM2 readouts loom.
8-K
Appoints seasoned CBL Officer
PepGen appointed Joseph Vittiglio, Esq., as Chief Business and Legal Officer on December 8, 2025. He brings over 20 years of biotech experience, including leading legal, compliance, financings, and product launches at bluebird bio and others—after consulting for PepGen this year. Leadership bolsters readiness for 2026 FREEDOM2-EDODM1 readouts.
8-K
Strong DM1 splicing data
PepGen reported Q3 2025 results, highlighting FREEDOM-DM1's 15 mg/kg cohort with 53.7% mean splicing correction—the highest yet in DM1 patients—after a single dose, well-tolerated overall. FREEDOM2's 5 mg/kg cohort stays on track for Q1 2026 readout, all enrolled. $115M financing extends cash runway to H2 2027. Expenses dropped; net loss narrowed to $18M.
DSGN
Design Therapeutics, Inc.
9.62+0.50
DYN
Dyne Therapeutics, Inc.
19.55-0.04
ENGN
enGene Holdings Inc.
8.38-0.05
ETNB
89bio, Inc.
14.84+0.00
EWTX
Edgewise Therapeutics, Inc.
22.77-1.17
NGNE
Neurogene Inc.
19.53-0.73
PBM
Psyence Biomedical Ltd.
1.53+0.05
PRME
Prime Medicine, Inc.
3.88-0.16
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RGNX
REGENXBIO Inc.
14.11+0.28